AU724267B2 - Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA - Google Patents

Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA Download PDF

Info

Publication number
AU724267B2
AU724267B2 AU28213/97A AU2821397A AU724267B2 AU 724267 B2 AU724267 B2 AU 724267B2 AU 28213/97 A AU28213/97 A AU 28213/97A AU 2821397 A AU2821397 A AU 2821397A AU 724267 B2 AU724267 B2 AU 724267B2
Authority
AU
Australia
Prior art keywords
rna
tumor
derived
apc
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU28213/97A
Other languages
English (en)
Other versions
AU2821397A (en
Inventor
David J. Boczkowski
Eli Gilboa
Smita K. Nair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2821397A publication Critical patent/AU2821397A/en
Application granted granted Critical
Publication of AU724267B2 publication Critical patent/AU724267B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AU28213/97A 1996-04-30 1997-04-30 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA Expired AU724267B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/640444 1996-04-30
US08/640,444 US5853719A (en) 1996-04-30 1996-04-30 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
PCT/US1997/007317 WO1997041210A1 (en) 1996-04-30 1997-04-30 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna

Publications (2)

Publication Number Publication Date
AU2821397A AU2821397A (en) 1997-11-19
AU724267B2 true AU724267B2 (en) 2000-09-14

Family

ID=42676767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28213/97A Expired AU724267B2 (en) 1996-04-30 1997-04-30 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA

Country Status (11)

Country Link
US (9) US5853719A (enExample)
EP (3) EP1721987B1 (enExample)
JP (2) JP3836151B2 (enExample)
AT (1) ATE346912T1 (enExample)
AU (1) AU724267B2 (enExample)
CA (1) CA2253632C (enExample)
DE (1) DE69737023T2 (enExample)
DK (1) DK0918848T3 (enExample)
ES (1) ES2277675T3 (enExample)
PT (1) PT918848E (enExample)
WO (1) WO1997041210A1 (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
US20050169898A1 (en) * 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7015204B1 (en) * 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2002258379A1 (en) * 2000-10-24 2002-09-19 Whitehead Institute For Biomedical Research Response of dendritic cells to a diverse set of pathogens
AU2002240197A1 (en) * 2001-02-01 2002-08-12 Tanox, Inc. Methods to generate and identify monoclonal antibodies to a large number of human antigens
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
JP2005526001A (ja) * 2001-10-04 2005-09-02 アグイラルーコルドバ，カリオス，エスツアルド 遺伝子療法用キメラ型ウイルスベクター
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
CN1665523A (zh) * 2002-07-05 2005-09-07 杜克大学 血管免疫疗法
WO2004016803A2 (en) * 2002-08-14 2004-02-26 Duke University Method of enhancing cd4+ t cell responses
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
AU2003297039B2 (en) * 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
WO2004074451A2 (en) * 2003-02-18 2004-09-02 Maxcyte, Inc. Loading of cells with antigens by electroporation
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
CA2546378A1 (en) * 2003-11-25 2005-06-09 Argos Therapeutics, Inc. Mrna transfected antigen presenting cells
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
CA2558382A1 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
WO2005116261A2 (en) * 2004-05-24 2005-12-08 Albert Einstein College Of Medecine Of Yeshiva University Rna expression microarrays
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
CA2577320C (en) * 2004-09-14 2019-08-13 Argos Therapeutics, Inc. Strain-independent amplification of pathogens and vaccines thereto
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
GB0501129D0 (en) * 2005-01-19 2005-02-23 Ribostem Ltd Method of treatment by administration of RNA
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
JP5095603B2 (ja) 2005-07-27 2012-12-12 オンコセラピー・サイエンス株式会社 結腸癌関連遺伝子ｔｏｍ３４
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP2010659B1 (en) 2006-04-14 2014-06-18 CellScript, Inc. Kits and methods for generating 5' capped RNA
CN104177464B (zh) 2006-08-18 2017-04-12 阿哥斯医疗公司 Cd83在联合治疗中的用途
CA2915560A1 (en) 2006-10-17 2008-04-24 Tomoaki Fujioka Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
US8513208B2 (en) * 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US8728806B2 (en) 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR101744514B1 (ko) 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2557089A2 (en) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
RU2633503C2 (ru) 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014010231A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
EP3888675A1 (en) 2013-09-24 2021-10-06 Duke University Compositions, methods and kits for eliciting an immune response
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US9610358B2 (en) * 2014-04-17 2017-04-04 Marker Gene Technologies, Inc Targeted pharmacological chaperones
US12214038B2 (en) * 2014-07-22 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
EP3178838B1 (en) 2014-08-04 2019-09-18 OncoTherapy Science, Inc. Koc1-derived peptide and vaccine including same
US10576097B2 (en) 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
RU2716716C2 (ru) * 2014-10-27 2020-03-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
JP2018090491A (ja) * 2015-04-01 2018-06-14 株式会社細胞治療技術研究所 癌ワクチンの製造方法、及び癌ワクチン
US11090332B2 (en) * 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
JP6666094B2 (ja) * 2015-09-15 2020-03-13 株式会社東芝 吸着支持装置、および物品把持装置
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
WO2018005769A1 (en) 2016-06-29 2018-01-04 Duke University Compositions and methods for activating antigen presenting cells with chimeric poliovirus
US12551556B2 (en) 2018-01-05 2026-02-17 Circular Biotech Ab Endogenous tumor-derived circular RNA and proteins thereof for use as vaccine
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
KR20260111629A (ko) * 2023-11-06 2026-07-15 이뮤니티바이오, 인크. 바이러스로 교육된 t 세포

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US5256536A (en) 1990-11-09 1993-10-26 Syntex (U.S.A.) Inc. Nucleotide probe for Neisseria gonrrhoeae
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JPH08502244A (ja) 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
DE4233430A1 (de) * 1992-10-05 1994-04-07 Basf Ag Verfahren zur Herstellung von 4-Hydroxymethyltetrahydropyran
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
DK0765386T3 (en) * 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0863913A4 (en) 1995-08-21 2001-04-11 Univ Duke METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US6228640B1 (en) * 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6831068B2 (en) * 2002-02-13 2004-12-14 Abbott Laboratories Macrolide antibacterial compounds
DE102004055330A1 (de) 2004-11-16 2006-05-24 Bosch Rexroth Aktiengesellschaft Verfahren und Vorrichtung zum Betreiben eines Netzwerkes

Also Published As

Publication number Publication date
CA2253632C (en) 2008-12-16
US6306388B1 (en) 2001-10-23
ES2277675T3 (es) 2007-07-16
DK0918848T3 (da) 2007-04-10
US20060057130A1 (en) 2006-03-16
US9115360B2 (en) 2015-08-25
PT918848E (pt) 2007-03-30
DE69737023D1 (de) 2007-01-11
EP2298927A3 (en) 2012-03-21
EP0918848A1 (en) 1999-06-02
US7601343B2 (en) 2009-10-13
EP1721987B1 (en) 2015-11-11
US6387701B1 (en) 2002-05-14
EP0918848A4 (en) 2004-05-12
AU2821397A (en) 1997-11-19
US20020018769A1 (en) 2002-02-14
US20100015108A1 (en) 2010-01-21
JP3955311B2 (ja) 2007-08-08
EP1721987A1 (en) 2006-11-15
ATE346912T1 (de) 2006-12-15
CA2253632A1 (en) 1997-11-06
US8263066B2 (en) 2012-09-11
WO1997041210A1 (en) 1997-11-06
EP0918848B1 (en) 2006-11-29
US20120288931A1 (en) 2012-11-15
US6670186B1 (en) 2003-12-30
JP2006254920A (ja) 2006-09-28
EP2298927A2 (en) 2011-03-23
US7101705B2 (en) 2006-09-05
US5853719A (en) 1998-12-29
DE69737023T2 (de) 2007-06-28
JP2000509281A (ja) 2000-07-25
US7105157B1 (en) 2006-09-12
JP3836151B2 (ja) 2006-10-18

Similar Documents

Publication Publication Date Title
US7601343B2 (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
Boczkowski et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
US5831068A (en) Method to increase the density of antigen on antigen presenting cells
Porgador et al. Induction of antitumor immunity using bone marrow-generated dendritic cells
Nair et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
EP1210430B1 (en) Muc-1 derived peptides
CA2347067C (en) Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
CN103570818A (zh) 肿瘤抗原性多肽及其作为肿瘤疫苗的用途
CN103570821A (zh) 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
HK1154631A (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
US20030044394A1 (en) Method for identifying and killing cancer cells
CN117903264A (zh) 新冠病毒SARS-CoV-2 HLA-A2限制性表位肽及应用
MXPA06007495A (en) Allogeneic tumor therapeutic agent
CN101168064A (zh) 重组人胰腺癌黏液蛋白核心肽dna疫苗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)